<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190306</url>
  </required_header>
  <id_info>
    <org_study_id>CXL-001</org_study_id>
    <nct_id>NCT01190306</nct_id>
  </id_info>
  <brief_title>Safety Study of the VEGA UV-A System to Treat Keratoconus</brief_title>
  <official_title>Safety and Effectiveness of the VEGA UV-A System for Corneal Collagen Cross-Linking in Eyes With Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the safety, tolerability, and effectiveness of
      corneal collagen cross-linking (CXL), when used to treat keratoconus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The sponsor terminated the study prior to data analysis for financial reasons.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Corneal Curvature</measure>
    <time_frame>6MO</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Corneal Curvature.</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>CXL Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eyes in the control group will be treated with riboflavin only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The VEGA UV-A Illumination System</intervention_name>
    <description>This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area</description>
    <arm_group_label>CXL Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin is a solution that will be delivered to the treatment area</description>
    <arm_group_label>CXL Treatment</arm_group_label>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 years of age or older

          -  Having a diagnosis of keratoconus

          -  Presence of central or inferior steepening

          -  Topography consistent with keratoconus

          -  Presence of one or more slit lamp or retinoscopy findings associated with keratoconus

          -  Contact lens wearers only:Removal of contact lenses for the required period of time

          -  Signed written informed consent

          -  Willingness and ability to comply with schedule for follow-up visits

        Exclusion Criteria:

          -  For keratoconus, a history of previous corneal surgery or the insertion of Intacs in
             the eye to be treated

          -  Corneal pachymetry â‰¤ 400 microns

          -  Previous ocular condition that may predispose the eye for future complications or
             prevent the possibility of improved vision

          -  A history of chemical injury or delayed epithelial healing in the eye(s) to be
             treated.

          -  Pregnancy (including plan to become pregnant) or lactation during the course of the
             study

          -  A known sensitivity to study medications

          -  Nystagmus or any other condition that would prevent a steady gaze during the
             cross-linking treatment or other diagnostic tests

          -  A condition that, in the investigator's opinion, would interfere with or prolong
             epithelial healing.

          -  Presence or history of any other condition or finding that, in the investigator's
             opinion, makes the patient unsuitable as a candidate for cross-linking or study
             participation or may confound the outcome of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barnet Dulaney Perkins Eye Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pamel Vision &amp; Laser Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSU Department of Ophthalmoloty</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revision Advanced Laser Eye Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Laser Consultants</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slade &amp; Baker Vision Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2010</study_first_submitted>
  <study_first_submitted_qc>August 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2010</study_first_posted>
  <results_first_submitted>December 13, 2012</results_first_submitted>
  <results_first_submitted_qc>January 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 4, 2013</results_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from August, 2010 to December 2011 from medical clinics throughout the country.</recruitment_details>
      <pre_assignment_details>Patients that were excluded from the clinical trial were considered screen failures due to not meeting one or more of the inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CXL Treatment</title>
          <description>Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.</description>
        </group>
        <group group_id="P2">
          <title>Sham Control</title>
          <description>Eyes in the control group will be treated with riboflavin only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CXL Treatment</title>
          <description>Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.</description>
        </group>
        <group group_id="B2">
          <title>Sham Control</title>
          <description>Eyes in the control group will be treated with riboflavin only.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="127"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B2" value="NA">The sponsor terminated the study prior to data analysis for financial reasons.</measurement>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Corneal Curvature</title>
        <time_frame>6MO</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Corneal Curvature.</title>
        <time_frame>6 Months</time_frame>
        <population>The CXL-001 study was completed but data analysis was not done. Prior to data analysis, the sponsor, Topcon, decided to terminate the study for administrative reasons only, and not as a result of any safety issues or concerns relating to the study.</population>
        <group_list>
          <group group_id="O1">
            <title>CXL Treatment</title>
            <description>Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.</description>
          </group>
          <group group_id="O2">
            <title>Sham Control</title>
            <description>Eyes in the control group will be treated with riboflavin only.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Corneal Curvature.</title>
          <population>The CXL-001 study was completed but data analysis was not done. Prior to data analysis, the sponsor, Topcon, decided to terminate the study for administrative reasons only, and not as a result of any safety issues or concerns relating to the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CXL Treatment</title>
          <description>Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.</description>
        </group>
        <group group_id="E2">
          <title>Sham Control</title>
          <description>Eyes in the control group will be treated with riboflavin only.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All such Confidential Information shall remain the property of Topcon, as applicable, and Institution agrees that neither it nor Principal Investigator nor any of its employees or Sub-Investigators, if any, shall disclose any of the Confidential Information to third parties, without the prior written consent of Topcon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Gibson</name_or_title>
      <organization>Topcon Medical Systems</organization>
      <phone>(201) 599-5121</phone>
      <email>RGIBSON@TOPCON.COM</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

